China Pharma Holdings (CPHI) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$651482.0.
- China Pharma Holdings' Net Income towards Common Stockholders rose 4172.33% to -$651482.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 3276.23%. This contributed to the annual value of -$4.7 million for FY2024, which is 5383.71% down from last year.
- According to the latest figures from Q3 2025, China Pharma Holdings' Net Income towards Common Stockholders is -$651482.0, which was up 4172.33% from -$528367.0 recorded in Q2 2025.
- Over the past 5 years, China Pharma Holdings' Net Income towards Common Stockholders peaked at -$475976.0 during Q1 2023, and registered a low of -$1.4 million during Q2 2024.
- Moreover, its 5-year median value for Net Income towards Common Stockholders was -$826669.0 (2021), whereas its average is -$902785.3.
- As far as peak fluctuations go, China Pharma Holdings' Net Income towards Common Stockholders crashed by 641855.51% in 2021, and later skyrocketed by 6326.01% in 2025.
- Over the past 5 years, China Pharma Holdings' Net Income towards Common Stockholders (Quarter) stood at -$980719.0 in 2021, then dropped by 28.9% to -$1.3 million in 2022, then increased by 2.53% to -$1.2 million in 2023, then increased by 0.63% to -$1.2 million in 2024, then soared by 46.79% to -$651482.0 in 2025.
- Its last three reported values are -$651482.0 in Q3 2025, -$528367.0 for Q2 2025, and -$785572.0 during Q1 2025.